- Editor's PickNicole Sinclair•16 hours ago
Pharmaceutical giant Mylan (MYL), which has recently dominated headlines over the skyrocketing 400% price increase of its allergy drug, made the decision on Monday to introduce a lower-priced generic EpiPen competitor. Above-average price inflation on Mylan’s EpiPen franchise is certainly nothing new. As Raymond James’ Elliot Wilbur pointed out: If you Google the term “EpiPen price increase(s),” you get over 120,000 hits from 2011 to just prior to this latest story breaking.
- Reuters•3 hours ago
The following are the top stories in the Wall Street Journal. - Donald Trump, hours after seeming to ease on his immigration and trade policy while standing with Mexico's president, told a crowd that all illegal immigrants are "subject to deportation" and that all those seeking legalization will have to go home and re-enter the country legally. - Dilma Rousseff, a former leftist guerrilla who defied a dictatorship but struggled as Brazil's president, was removed from office Wednesday following an impeachment trial she condemned as a coup.
- Consumer Reports•11 hours ago
Faced with skyrocketing costs, several readers have told us they've ordered EpiPens from Canada as a way to save money. But we found that there are safer, cheaper options for getting these life-s...
Mylan N.V. (MYL)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||42.03 x 200|
|Ask||42.39 x 100|
|Day's Range||41.87 - 42.63|
|52wk Range||37.59 - 55.51|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||26.81|
|Avg Vol (3m)||5,292,347|
|Dividend & Yield||0.00 (0.00%)|